Open access

448 Clinical outcomes and safety of immune checkpoint inhibitors (ICI) in patients with solid tumors and paraneoplastic syndromes (PNS)
Amin Nassar, Talal El Zarif, Ahmed Bilal Khalid, Serena J Rahme, Lucia Kwak, Marita Salame, Elias Bou Farhat, Edward El Am, Arjun Ravishankar, Bachar Ahmad, Frank Aboubakar Nana, David Kaldas, Abdul Rafeh Naqash, Elad Sharon, Nicole R Leboeuf, Alessio Cortellini, Andrea Malgeri, Shruti Gupta, Jeffrey A Sparks, Jenny Linnoila, Ole-Petter R Hamnvik, Kaushal Parikh, Rana McKay, Thomas Dilling, Toni K Choueiri, Elio Adib, Elie Najem, So Yeon Kim, Guru P Sonpavde

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A498; DOI: 10.1136/jitc-2023-SITC2023.0448
449 Polygenic risk scores for liver injury are associated with the risk for autoimmune hepatitis in patients treated with atezolizumab
Ashis Saha, Cameron Adams, David Roe, Mark McCarthy, Ira Mellman, Rajat Mohindra, G Scott Chandler, Christian Hammer

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A499-A500; DOI: 10.1136/jitc-2023-SITC2023.0449
450 Safety of immune checkpoint inhibitors in cancer patients with HIV – real world outcomes
Muhammad Junaid Tariq, Ahmed Al-Alwan, Mostafa Aglan, Muhammad Awidi

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A501; DOI: 10.1136/jitc-2023-SITC2023.0450
451 Outcomes of patients with unresectable hepatocellular carcinoma who developed an infection while receiving Atezolizumab
Abdullah Esmail, Jiaqiong Xu, Ethan Burns, Kelly Gee, Catherine Wiechmann, Yuqi Zhang, Ryan Kieser, Godsfavour Umoru, Shivan Shah, Kai Sun, Maen Abdelrahim

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A502; DOI: 10.1136/jitc-2023-SITC2023.0451
452 Braicitinib treatment reduced the expansion of CD8+ T cells in C3H mice with skin grafts-induced alopecia areata
Hao Yi, Xiao Jian, Yaxin Cai, Chunhui He, Yanping Yuan, Xiangnan Qiang, Ruiqing Yan, Nan Xie

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A503; DOI: 10.1136/jitc-2023-SITC2023.0452
453 Selective delivery of TGFβ ‘trap’ to CD39-expressing immune and stroma cells reshapes tumor microenvironment and rejuvenates antitumor immunity
Hongtao Lu, Dawei Sun, Jun Sun, Quan Qiu, Rui Gao, Yehua Zhu, Xiaoli Guo, Yefeng Lu, Yanan Geng, Liliang Xia, Shun Lu

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A504; DOI: 10.1136/jitc-2023-SITC2023.0453
454 Checkpoint modification of early T cell activation provides enhanced anti-tumor activity and survival benefits in a fast-growing preclinical tumor challenge model
Mohsen Mohammadi, Xiang Y Zhou, Zhi Xiang, Wynetta Giles-Davis, Andrew Luber, Sue L Currie, Hildegund CJ Ertl

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A505; DOI: 10.1136/jitc-2023-SITC2023.0454
455 Establishing an effective xenograft mouse model: replicating human immune cell infiltration in colon adenocarcinoma for enhanced immunotherapy testing
Emilie Bayon, Audrey Wetzel, Arije Mersni, Kiave Yune Ho Wang Yin

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A506; DOI: 10.1136/jitc-2023-SITC2023.0455
456 100% complete response to PEEL-224 in combination with PD-1 blockade in a syngeneic mouse model of colon cancer
Aleah F Caulin, Sophia Howard, Trent Fowler, Ivan Alferiev, Michael Chorny, Garrett Brodeur, Debra Thoma Vallner, Robert G Maki, Joshua D Schiffman

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A507; DOI: 10.1136/jitc-2023-SITC2023.0456
457 Targeting FASN sensitizes irradiated glioblastoma to immune checkpoint blockade
Mara De Martino, Camille Daviaud, Claire Vanpouille-Box

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A508; DOI: 10.1136/jitc-2023-SITC2023.0457

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages